The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Stage

Acquired Unit | Acquired

Valuation

$0000 

About Nimbus Therapeutics - Nimbus Therapeutic and Acetyl-CoA Carboxylase (ACC) Inhibitor Program

Nimbus Therapeutics, formerly Nimbus Discovery, harnesses the power of computational chemistry to design breakthroughs for the treatment of substantial and underserved human diseases. The company's focus on metabolic diseases, cancer and immune-inflammatory disorders is driven by its selection of well validated targets that have proven intractable to the approaches taken by others in the pharmaceutical and biotechnology industry. Using its unique approach and technological capabilities, Nimbus is rapidly progressing highly selective and potent small molecules through discovery and development. The company's advanced programs include ACC, IRAK4, and Tyk2. Nimbus is headquartered in Cambridge, Massachusetts (USA).

Nimbus Therapeutics - Nimbus Therapeutic and Acetyl-CoA Carboxylase (ACC) Inhibitor Program Headquarter Location

25 First Street Suite 404

Cambridge, Massachusetts, 02141,

United States

857-999-2009

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Nimbus Therapeutics - Nimbus Therapeutic and Acetyl-CoA Carboxylase (ACC) Inhibitor Program

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Nimbus Therapeutics - Nimbus Therapeutic and Acetyl-CoA Carboxylase (ACC) Inhibitor Program is included in 1 Expert Collection, including Cancer.

C

Cancer

1,179 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

  • Where is Nimbus Therapeutics - Nimbus Therapeutic and Acetyl-CoA Carboxylase (ACC) Inhibitor Program's headquarters?

    Nimbus Therapeutics - Nimbus Therapeutic and Acetyl-CoA Carboxylase (ACC) Inhibitor Program's headquarters is located at 25 First Street, Cambridge.

  • What is Nimbus Therapeutics - Nimbus Therapeutic and Acetyl-CoA Carboxylase (ACC) Inhibitor Program's latest funding round?

    Nimbus Therapeutics - Nimbus Therapeutic and Acetyl-CoA Carboxylase (ACC) Inhibitor Program's latest funding round is Acquired Unit.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.